Reply
Fei Wang, Jing Wang, Yaru Li, Jing Yuan, Ping Yao, Sheng Wei, Huan Guo, Xiaomin Zhang, Handong Yang, Tangchun Wu, Meian He – 1 March 2019
Fei Wang, Jing Wang, Yaru Li, Jing Yuan, Ping Yao, Sheng Wei, Huan Guo, Xiaomin Zhang, Handong Yang, Tangchun Wu, Meian He – 1 March 2019
Naoko Ohtani, Norifumi Kawada – 1 March 2019 – The gut and the liver are anatomically and physiologically connected, and this “gut–liver axis” exerts various influences on liver pathology. The gut microbiota consists of various microorganisms that normally coexist in the human gut and have a role of maintaining the homeostasis of the host. However, once homeostasis is disturbed, metabolites and components derived from the gut microbiota translocate to the liver and induce pathologic effects in the liver.
Peng Tang, Heng Boon Low, Chin Wen Png, Federico Torta, Jaspal Kaur Kumar, Hwee Ying Lim, Yi Zhou, Henry Yang, Veronique Angeli, Asim Shabbir, E. Shyong Tai, Richard A. Flavell, Chen Dong, Markus R. Wenk, Dan Yock Yang, Yongliang Zhang – 1 March 2019 – Nonalcoholic fatty liver disease is currently the most common liver disease and is a leading cause of liver‐related morbidity and mortality. However, its pathogenesis remains largely unclear.
1 March 2019
Christopher J. Danford, Ghideon Ezaz – 1 March 2019
Steven M. Kawut, Susan S. Ellenberg, Michael J. Krowka, David Goldberg, Hugo Vargas, David Koch, Tiffany Sharkoski, Nadine Al‐Naamani, Alyson Fox, Robert Brown, Joshua Levitsky, Jae K. Oh, Grace Lin, Nianfu Song, Carl Mottram, Margaret F. Doyle, David E. Kaplan, Samir Gupta, Michael B. Fallon – 28 February 2019 – The tyrosine kinase inhibitor sorafenib improves hepatopulmonary syndrome (HPS) in an experimental model. However, the efficacy and adverse effect profile in patients with HPS are unknown.
Jaclyn LoPiccolo, Michael I. Brener, Kiyoko Oshima, Evan J. Lipson, James P. Hamilton – 28 February 2019
28 February 2019
28 February 2019
28 February 2019